Perhaps someone more knowledgeable could clarify the following:
- If at the 45% readout (or even the 60%) it is deemed that the treatment is showing outstanding results (as we all expect and hope for ) ie "Overwhelming efficacy" and the decision is made to continue the trial, does it continue with the placebo arm?
- I ask as effectively that would be subjecting those remaining to be enlisted (to complete the trial) with a 50:50 chance of survival (obviously not exactly 50:50 due to improved SOC and Rem-l may not be 100% effective).
- It does raise ethical questions
- Is there any obligation to inform the market (company) or could/would they just announce "the trial is continuing" with out any reference to the results?
- Forums
- ASX - By Stock
- MSB
- Ann: Phase 3 Trial in COVID-19 ARDS Surpasses 50% Enrollment
Ann: Phase 3 Trial in COVID-19 ARDS Surpasses 50% Enrollment, page-218
-
- There are more pages in this discussion • 228 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
$1.12 |
Change
0.010(0.90%) |
Mkt cap ! $1.270B |
Open | High | Low | Value | Volume |
$1.13 | $1.16 | $1.10 | $6.926M | 6.195M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 33708 | $1.18 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.06 | 5431 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 33417 | 1.175 |
2 | 4375 | 1.170 |
3 | 2697 | 1.155 |
5 | 39433 | 1.145 |
1 | 1974 | 1.135 |
Price($) | Vol. | No. |
---|---|---|
1.055 | 5431 | 3 |
1.060 | 35 | 1 |
1.070 | 26235 | 1 |
1.085 | 1686 | 2 |
1.095 | 7974 | 2 |
Last trade - 15.59pm 08/07/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |